What It Means for
Clinical Practice

Evidence suggests that Optiflow™ Nasal High Flow (NHF) reduces escalation, reduces mortality rates, improves symptomatic relief and promotes compliance.

Large randomized controlled trials using Optiflow™ have been published in some of the world's most prestigious medical journals. Discover what Optiflow™ can do for your clinical practice.



  • Significantly reduces intubation rate when PaO2:FiO2 ≤200 mm Hg
    Frat et al. New Engl J Med. 2015.



  • Reduces escalation to non-invasive ventilation and re-intubation
    Maggiore et al. AJRCCM. 2014.
    Parke et al. Respir Care. 2011.
    Hernández et al. JAMA. 2016. 

  • Non-inferior to Bi-level Positive Airway Pressure
    Stéphan et al. JAMA. 2015.

  • Significantly reduces 90-day mortality

Frat et al. New Engl J Med. 2015


  • Significantly reduced intensity of respiratory discomfort and dyspnea
    Frat et al. New Engl J Med. 2015.

  • Significantly less dyspnea compared with face mask
    Roca et al. Respir Care. 2010.

  • Rapid and sustained improvement of dyspnea in patients with respiratory distress in the emergency department
    Lenglet et al. Respir Care. 2012.
  • Well tolerated
    Sztrymf et al. Intensive Care Medicine. 2011.
  • Greater overall comfort than face mask
    Roca et al. Respir Care. 2010
    Lenglet H. et al. Respir Care. 2012.
  • Heating and humidification of gas improves patient comfort and tolerance of therapy
    Maggiore et al. Am J Respir Crit Care Med. 2014.
  • Significantly less skin breakdown than BPAP
    Stéphan et al. JAMA. 2015
  • Lower nurse workload noted, compared with BPAP
    Stéphan et al. JAMA. 2015

Discover How These Lead To Health Economic Benefits